Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 149-155

  Nilius, Angela M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

AZD 2563; Linezolid; Multidrug resistant Gram positive pathogens; New antibacterial agents; Oxazolidinone; Ranbezolid

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFECTIVE AGENT; BACTERIAL RNA; CHLORAMPHENICOL; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; ERYTHROMYCIN; GENTAMICIN; LINCOMYCIN; LINEZOLID; METICILLIN; MONOAMINE OXIDASE INHIBITOR; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PHENYLPROPANOLAMINE; POSIZOLID; PROTEIN SYNTHESIS INHIBITOR; PSEUDOEPHEDRINE; RANBEZOLID; RNA 23S; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TOLOXATONE; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; XA 043;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMMUNICABLE DISEASE; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FOOD DRUG INTERACTION; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HALOBACTERIUM SALINARUM; HEADACHE; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; REVIEW; SEROTONIN SYNDROME; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION; SYSTOLIC HYPERTENSION; THROMBOCYTOPENIA; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; OXAZOLIDINONES;

EID: 0037303362     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, Bartholomew PT, Gregory WA, Forbes M: Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP-105 and DuP-721. Antimicrob Agents Chemother (1987) 31(11):1791-1797.
2. Hutchinson DK: Oxazolidinone antibacterial agents: A critical review. Curr Topics Med Chem (2003): in press. This recent review contains a detailed discussion of the structure-activity relationships in the oxazolidinone class.
3. Eustice DC, Feldman PA, Slee AM: The mechanism of action of DuP-721, a new antibacterial agent: Effects on macromolecular synthesis. Biochem Biophys Res Commun (1988) 150(3):965-971.
4. Shinabarger DI, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM: Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother (1997) 41(10):2132-2136.
5. Lin AH, Murray RW, Vidmar TJ, Marotti KR: The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother (1997) 41(10):2127-2131.
6. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob Agents Chemother (2002) 46(3):625-629.
7. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL: The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother (1998) 42(12):3251-3255..
8. Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC, Shinabarger DL, Ganoza MC: Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother (2002) 46(4):1080-1085.
9. Patel U, Yan YP, Hobbs FW Jr, Kaczmarczyk J, Slee AM, Pompliano DL, Kurilla MG, Bobkova EV: Oxazolidinones mechanism of action: Inhibition of the first peptide bond formation. J Biol Chem (2001) 276(40):37199-37105.
10. Burghadt H, Schmitz K-L, Müller M: On the target of a novel class of antibiotics, oxazolidinones, active against multidrug-resistant Gram-positive bacteria. FEBS Lett (1998) 425(1):40-44.
11. Kloss P, Xiong L, Shinabarger DL, Mankin AS: Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl-transferase center. J Mol Biol (1999) 294(1):93-101.
12. Thompson J, O'Connor M, Mills JA, Dahlberg AE: The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol (2002) 322(2):273-279.
13. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE: Oxazolidinone resistance is associated with a mutation in the peptidyl-transferase region of 23S rRNA. ICAAC (1998) 38: Abs 104.
14. Murray RW, Schaadt RD, Zurenko GE, Marotti KR: Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay. Antimicrob Agents Chemother (1998) 42(4):947-950.
15. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA: Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother (2001) 45(7):2154-2156.
16. Xiong L, Kloss P, Douthwaite S, Andersen NM, Swaney S, Shinabarger DL, Mankin AS: Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol (2000) 182(19):5325-5331.
17. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 358(9277):207-208. First report of a linezolid-resistant strain of S aureus isolated from a patient on linezolid treatment.
18. Zurenko GE, Todd WM, Hafkin B, Meyers B, Kauffman C, Bock J, Slightom J, Shinabarger D: Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. ICAAC (1999) 39: Abs 848.
19. Jones RN, Della-Latta P, Lee LV, Beidenbach DJ: Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis (2002) 42(2):137-139.
20. Herrero IA, Issa NC, Patel R: Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Eng J Med (2002) 346(11):867-869. Describes transmission of a linezolid-resistant strain of E faecium, which developed in a patient treated with linezolid, to other patients in the same transplantation unit who had not been treated with linezolid.
21. Woolford N, Tysall L, Auckland C, Stockdale MW, Lawson AJ, Walker RA, Livermore DM: Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by RT-PCR and PCR restriction fragment length polymorphism analysis. J Clin Microbiol (2002) 40(11):4298-4300.
22. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP: Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother (2002) 50(5):743-746.
23. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB: Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother (2002) 46(10):3334-3336. Describes the impact of the copy number changes of rDNA on the linezolid minimum inhibitory concentration.
24. Anderegg TR, Biedenbach DJ, Jones RN: In vitro evaluation of AZD-2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob Agents Chemother (2002) 46(8):2662-2664.
25. Fluit AC, Schmitz F-J, Verhoef J, Milatovic D: In vitro activity of AZD-2563, a novel oxazolidinone, against European Gram-positive cocci. J Antimicrob Chemother (2002) 50(2):271-276. Comprehensive comparative study of the antibacterial activity of AZD-2563 and linezolid with 1543 staphylococci, enterococci and streptococci using reference methods of the National Committee for Clinical Laboratory Standards (USA).
26. Eliopoulos GM, Wennersten CB, Moellering RC Jr: In vitro activity of AZD-2563, against enterococci. Antimicrob Agents Chemother (2002) 46(10):3273-3275.
27. Baum SE, Crawford SA, McElmeel ML, Whitney CG, Jorgensen JH: Comparative activities of the oxazolidinone AZD-2563 and linezolid against selected recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2002) 46(9):3094-3095.
28. Peric M, Lin G, Clark CL, Jacobs MR, Appelbaum PC: Anti-pneumococcal activity of AZD-2563, a new oxazolidinone, compared with nine other agents. J Antimicrob Chemother (2002) 50(1):95-100.
29. Wootton M, Howe RA, Walsh TR, Bennett PM, MacGowan AP: In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother (2002) 50(5):760-761. Reports the activity of linezolid against vancomycin-resistant S aureus.
30. Rattan A, Mehta A, Das B, Pandya M, Bhateja P, Mathur T, Singhal S, Sood R, Malhotra S, Yadav A, Ray A et al: In vitro activity of RBx7644, an extended spectrum investigational oxazolidinone. ICAAC (2002) 42:Abs 1288.
31. Ednie LM, Jacobs MR, Appelbaum PC: Anti-anaerobic activity of AZD-2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother (2002) 50(1):101-105.
32. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Hutchinson DK, Barbachyn MR, Brickner SJ: In vitro antibacterial activity of U-100592 and U-100766, novel oxazolidinone antibiotics. ICAAC (1995) 35:Abs 216.
33. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma hominis, M pneumoniae and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones. Antimicrob Agents Chemother (2001) 45(9):2604-2608.
34. Reidl B, Endermann R: Recent developments with oxazolidinone antibiotics. Exp Opin Ther Pat (1999) 9(5):625-633.
35. Zyvox: Linezolid injection, linezolid tablets, linezolid for oral suspension. Pharmacia Corp Package insert (2002).
36. Eliopoulos GM: Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis (2003) 36(4):473-481. Opinion paper sponsored by the Antimicrobial usage and Clinical Trials Committee of Infectious Diseases Society of America.
37. Perry CM, Jarvis B: Linezolid: A review of its use in the management of serious Gram-positive infections. Drugs (2001) 61(4):525-551. Review of studies leading to the regulatory approval of linezolid.
38. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2002) 34(11):1481-1490.
39. Hartman CS, Leach TS, Kaja RW, Schaser RJ, Todd WM, Hafkin B: Linezolid in the treatment of vancomycin-resistant enterococcus: A dose-comparative, multicenter phase III trial. ICAAC (2000) 40:Abs 2235.
40. Chien JW, Kucia ML, Salata RA: Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin Infect Dis (2000) 30(1):146-151.
41. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ: Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother (2002) 46(8):2723-2726. Analysis of clinical trial data with regard to the incidence of thrombocytopenia.
42. Attassi K, Hershberger E, Alam R, Zervos MJ: Thrombocytopenia associated with linezolid therapy. Clin Infect Dis (2002) 34(5):695-698. An analysis of patients on linezolid for incidence of thrombocytopenia.
43. Orrick JJ,. Johns T, Janelle J, Ramphal R: Thrombocytopenia secondary to linezolid administration: What is the risk? Clin Infect Dis (2002) 35(3):348-349.
44. Abena PA, Mathieux VG, Scheiff J-M, Michaux LM, Vandercam BC: Linezolid and reversible myelosuppression. J Am Med Assoc (2001) 286(16):1973.
45. Monson T, Schichman SA, Zent CS: Linezolid-induced pure red cell aplasia. Clin Infect Dis (2002) 35(3):E29-E31.
46. Green SL, Maddox JC, Huttenbach ED: Linezolid and reversible myelosuppression. J Am Med Assoc (2001) 285(10):1291.
47. Halpren M: Linezolid-induced pancytopenia. Clin Infect Dis (2002) 35(3):347-348.
48. Waldrep TW, Skiest DJ: Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy (2002) 22(1):109-112.
49. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK: Linezolid: Pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol (2001) 41(5):563-572.
50. Antal EJ, Hendersot PE, Batts DH, Sheu W-P, Hopkins NK, Donaldson KM: Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol (2001) 41(5):552-562.
51. Wigen CL, Goetz MB: Serotonin syndrome and linezolid. Clin Infect Dis (2002) 34(12):1651-1652.
52. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K. Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet (2001) 357(9263):1179.
53. Anderegg T, Biedenbach D, Kirby J, Jones RN: Proposed susceptibility testing criteria for AZD-2563, a novel long-acting oxazolidinone (OXA). ICAAC (2002) 42:Abs 1308.
54. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, PetrolattiJM, Quinn JP: Risk factors associated with the development of infection with linezolid and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 35(10):1269-1272. Discussion of the factors associated with the emergence of linezolid-resistant E faecium.